Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases

(2021) Jake A Ruddy et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

(2021) Hana M. El Sahly et al.   NEW ENGLAND JOURNAL OF MEDICINE

COVID-19 Vaccination Coverage Among Adults — United States, December 14, 2020–May 22, 2021

(2021) Jill Diesel et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

(2021) Wesley H. Self et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity

(2021) Mark W. Tenforde et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence of Multiple Chronic Conditions Among US Adults, 2018

(2020) Peter Boersma et al.   Preventing Chronic Disease

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE